Updated:
Berunda Capital Management
Berunda Capital Management is a healthcare-focused venture capital firm in Bangalore, India, founded by Dr. Abhijit Bhattacharya in 2020.
Berunda Capital Management
Berunda Capital Management was launched in 2020 by Dr. Abhijit Bhattacharya, a veteran with over two decades in pharmaceuticals and venture capital, including leadership roles at Novo Nordisk and Sequoia Capital India. The firm focuses exclusively on healthcare and life sciences, reflecting the founders' deep domain expertise. The firm invests across the full spectrum of healthcare innovation — biotech, pharmaceuticals, medical devices, diagnostics, and healthtech. Berunda typically leads or co-leads rounds from seed through Series C, deploying growth capital and often taking board seats. Its portfolio includes companies such as Mitra Biotech, a precision oncology platform, and Eyestem, a stem-cell therapy company targeting retinal diseases. Berunda is headquartered in Bangalore, India, and operates as a single-fund venture firm. The team includes professionals with backgrounds in drug discovery, clinical development, and investment banking. The firm closed its first fund, Berunda Capital Fund I, in 2021 at $100 million, backed by global institutional investors and family offices (per VCCircle, 2021). The structural differentiator is Berunda's focused mandate on Indian healthcare innovation — a sector historically underserved by venture capital. The firm combines scientific vetting with commercial scaling, positioning itself as a bridge between Indian research and global pharmaceutical markets. This thesis is rare among Indian VCs, who typically prioritize tech and consumer.
General information
Firm type
Venture Capital
Year founded
2020
AUM
Undisclosed
Location
Region
Asia
Country
India
City
Bangalore
Corporate office
Bangalore, Karnataka, India
Sector focus
Frequently asked questions
Who runs investment decisions at Berunda Capital Management?
Dr. Abhijit Bhattacharya, founder and managing partner, leads investment decisions. He previously served as a managing director at Sequoia Capital India and in senior R&D roles at Novo Nordisk. The investment committee includes partners with deep scientific and commercial expertise.
What investment stages does Berunda typically target?
Berunda invests across seed to growth stages, with a typical check size of $1–10 million. The firm prefers leading or co-leading rounds and often takes board seats in portfolio companies (per VCCircle).
Which sectors does Berunda explicitly focus on?
Berunda is exclusively focused on healthcare and life sciences: biotech, pharmaceuticals, medical devices, diagnostics, and healthtech. It avoids consumer internet, enterprise software, and fintech.
Is Berunda a single-family office or a venture firm?
Berunda is an independent venture capital firm raising capital from institutional investors and family offices. It is not structured as a family office.
What is the geographic focus of Berunda's investments?
Berunda focuses exclusively on India-domiciled companies. Its portfolio includes firms based in Bangalore, Mumbai, Hyderabad, and other Indian biotech hubs.
Does Berunda invest in syndicates or as a lead investor?
Berunda typically leads or co-leads rounds and takes board seats. It collaborates with other healthcare-dedicated VCs and strategic investors for larger rounds.
What is the relationship between Berunda and its portfolio companies?
Berunda provides hands-on support in strategy, clinical development, regulatory pathways, and business development. The team's prior pharma experience helps portfolio companies navigate drug approval and licensing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: